Clinical Trials Search Tool
Moderate-to-Severe Psoriasis Study
Enrollment Opens: 02-22-2022
Enrollment Closes: TBD
Decreasing resident memory T cells while increasing clinical durability: higher induction doses of risankizumab for moderate-to-severe plaque psoriasis (KNOCKOUT). One year study requires participants to have had psoriasis for at least six months. Participants cannot have previously been exposed to risankizumab.
Study ID: OMRC-000141
To Enroll: Visit http://www.oregonmedicalresearch.com to learn more and fill out contact form, or call 503-245-1525.
Posted by: Oregon Medical Research Center | http://www.oregonmedicalresearch.com